News | March 10, 2026
GAIA and Daiichi Sankyo Europe join forces to launch groundbreaking digital therapeutic for heart health
Germany will be the first launch market
Germany will be the first launch market
The hospitals house over 25 super-speciality centres and Centres of Excellence in Cardiology, Neurology, Oncology, Paediatrics, Orthopaedics, ENT, Obstetrics and Gynaecology, General Surgery, Internal Medicine, Critical Care, and Chronic Disease Management
Huwel’s diagnostic solutions leverage open RT-PCR system
Gazyva/Gazyvaro outperformed placebo across all key and secondary endpoints
It is also approved for?AIDS-related Kaposi sarcoma?after failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients with Kaposi sarcoma
Moderna will appeal to the Federal Circuit to assert that its government-contractor immunity limits liability under federal law
Achondroplasia, a rare genetic disorder, causes skeletal dysplasia and often increases the risk of muscular, neurological, and cardiorespiratory complications
The EIR was issued following an inspection of the facility from November 10 to November 21, 2025
Zydus has in-licensed FYB206, a proposed biosimilar to immuno-oncology therapy Keytruda (pembrolizumab), exclusively from Formycon AG for the U.S. and Canadian markets
The oral therapy is aimed at adults with chronic spontaneous urticaria (CSU) who do not respond adequately to H1-antihistamines
Subscribe To Our Newsletter & Stay Updated
